Century Therapeutics
IPSC
57 hedge funds and large institutions have $10.1M invested in Century Therapeutics in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 29 reducing their positions, and 13 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
2.74% less ownership
Funds ownership: 26.25% → 23.5% (-2.7%)
12% less funds holding
Funds holding: 65 → 57 (-8)
20% less capital invested
Capital invested by funds: $12.6M → $10.1M (-$2.52M)
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
69% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$304K |
| 2 |
Two Sigma Advisers
New York
|
+$264K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$222K |
| 4 |
Two Sigma Investments
New York
|
+$183K |
| 5 |
Squarepoint
New York
|
+$105K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$1.01M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$447K |
| 3 |
Jane Street
New York
|
-$208K |
| 4 |
BlackRock
New York
|
-$175K |
| 5 |
Goldman Sachs
New York
|
-$116K |
IPSC Hedge Fund Activity: Q3 2025 in Review
57 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Century Therapeutics (IPSC) for Q3 2025, worth a combined $10.1M — down 20% from $12.6M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of IPSC and 5 opened new positions — a net loss of 8 holders — while 29 trimmed existing stakes and 9 added.
The largest buyer was Renaissance Technologies, adding an estimated $304K. The largest seller was Bain Capital Life Sciences Investors, cutting an estimated $1.01M.
- 57 institutional investors held Century Therapeutics (IPSC) as of Q3 2025, down from 65 in Q2 2025.
- Funds reported $10.1M of Century Therapeutics stock for Q3 2025, down 20% quarter-over-quarter.
- 5 funds opened new Century Therapeutics positions in Q3 2025 and 13 closed out, a net change of -8 holders.
- The largest Century Therapeutics buyer in Q3 2025 was Renaissance Technologies, an estimated $304K added.
- The largest Century Therapeutics seller in Q3 2025 was Bain Capital Life Sciences Investors, an estimated $1.01M sold.
Based on aggregated 13F filings for Q3 2025.